Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss First Quarter Results of Fiscal Year 2008
November 09 2007 - 8:00AM
PR Newswire (US)
WEIFANG, China, Nov. 9 /Xinhua-PRNewswire-FirstCall/ -- Shengtai
Pharmaceutical, Inc. (OTC:SGTI) (BULLETIN BOARD: SGTI) ("Shengtai
Pharmaceutical" or "the Company"), a leading manufacturer and
distributor of high-quality, pharmaceutical grade glucose products
in China and glucose and starch products that serve as raw
materials for food, beverage and industrial production, today
announced that it will conduct a conference call at 8:00 a.m.
Eastern Time on Thursday, November 15, 2007 to discuss the first
quarter results of fiscal year 2008. Shengtai Pharmaceutical's
Chief Financial Officer, Mr. Philips Zhang will be participating in
the conference call. The Company plans to make an earnings
announcement prior to the call. To participate in the live
conference call, please dial the following number five to ten
minutes prior to the scheduled conference call time: 888- 419-5570.
International callers should dial 617-896-9871. When prompted by
the operator, mention Conference Passcode 17815721. If you are
unable to participate in the call at this time, a replay will be
available for seven days starting on Thursday, November 15 at 10:00
a.m. Eastern Time. To access the replay, dial 888-286-8010,
international callers should dial 617-801-6888, and enter the
passcode 96335341. About Shengtai Pharmaceutical, Inc. Shengtai
Pharmaceutical, Inc. through its wholly-owned subsidiary Shengtai
Holding, Inc. (SHI), a New Jersey corporation, and the Chinese
operating company of Weifang Shengtai Pharmaceutical Co., Ltd., is
a leading manufacturer and supplier of glucose products, which
include pharmaceutical grade glucose used for medical purposes, and
glucose and cornstarch products for the food and beverage industry
and for industrial production in China. For more information about
Shengtai Pharmaceutical, Inc. please visit
http://www.shengtaipharmaceutical.com/ . Safe Harbor Statement Safe
Harbor Statement Under the Private Securities Litigation Reform Act
of 1995: Certain statements in this press release and oral
statements made by the Company, constitute forward-looking
statements for purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995. These statements
include, without limitation, statements regarding our ability to
prepare the company for growth, the Company's planned capacity
expansion in 2007 and predictions and guidance relating to the
Company's future financial performance. We have based these
forward-looking statements largely on our current expectations and
projections about future events and financial trends that we
believe may affect our financial condition, results of operations,
business strategy and financial needs but they involve risks and
uncertainties that could cause actual results to differ materially
from those in the forward-looking statements, which may include,
but are not limited to, such factors as unanticipated changes in
product demand especially in the pharmaceutical industry, pricing
and demand trends for the Company's products, changes to government
regulations, risk associated with operation of the Company's new
facilities, risk associated with large scale implementation of the
company's business plan, the ability to attract new customers,
ability to increase its product's applications, cost of raw
materials, downturns in the Chinese economy, and other information
detailed from time to time in the Company's filings and future
filings with the United States Securities and Exchange Commission.
Investors are urged to consider these factors carefully in
evaluating the forward-looking statements herein and are cautioned
not to place undue reliance on such forward-looking statements,
which are qualified in their entirety by this cautionary statement.
The forward-looking statements made herein speak only as of the
date of this press release and the Company undertakes no duty to
update any forward-looking statement to conform the statement to
actual results or changes in the company's expectations. For more
information, please contact: Company Contact: Mr. Philips Zhang CFO
Shengtai Pharmaceutical, Inc. Tel: +86-536-629-5728 Email: Investor
Relations Contact: Mr. Crocker Coulson President CCG Elite Investor
Relations Tel: +1-646-213-1915 (NY Office) Email: DATASOURCE:
Shengtai Pharmaceutical, Inc. CONTACT: Company Contact - Mr.
Philips Zhang, CFO of Shengtai Pharmaceutical, Inc.,
+86-536-629-5728, or ; or Investor Relations Contact - Mr. Crocker
Coulson, President of CCG Elite Investor Relations, +1-646-213-1915
(NY Office), or , for Shengtai Pharmaceutical, Inc. Web Site:
http://www.shengtaipharmaceutical.com/
Copyright